Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
State Street Corporation reports beneficial ownership of 28,490,638 shares of Recursion Pharmaceuticals Inc. The filing states 03/31/2026 and reports ownership equal to 5.5% of the outstanding common stock. The filing lists shared voting power of 27,368,965 and shared dispositive power of 28,490,638.
The report names several State Street-affiliated investment adviser subsidiaries as relevant holders. The signature block shows the filing was signed on 05/12/2026 by a State Street officer.
Recursion Pharmaceuticals director Christopher Gibson reported multiple stock movements in Class A and Class B shares. He sold 40,000 shares of Class A Common Stock at $3.37 per share in an open-market transaction and made a bona fide gift of 20,000 shares, both on May 7, 2026, under a pre-arranged Rule 10b5-1 trading plan. He also converted 60,000 shares of Class B Common Stock into 60,000 shares of Class A Common Stock. After these transactions, he directly holds 906,556 shares of Class A Common Stock. The filing also lists several outstanding stock option awards with exercise prices between $2.48 and $10.09, expiring between 2030 and 2035, and indirect holdings of Class B shares through family entities.
RECURSION PHARMACEUTICALS, INC. director Blake Borgeson completed an open-market sale of 30,000 shares of Class A Common Stock at $3.52 per share. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 31, 2025. Following this sale, Borgeson directly owns 6,199,863 shares of Class A Common Stock, so the transaction represents a small portion of his overall reported holdings.
Christopher C. Gibson filed notices of proposed sales of Class A shares under Form 144. The excerpt lists four sale entries: 40,000 shares on 02/19/2026 for $138,400.00, 40,000 shares on 03/23/2026 for $130,000.00, 40,000 shares on 04/07/2026 for $124,000.00, and 40,000 shares on 04/22/2026 for $144,400.00. The filing identifies the broker as Fidelity Brokerage Services LLC and lists the trading venue as NASDAQ.
Recursion Pharmaceuticals reported a smaller quarterly loss while tightening spending and maintaining a strong cash position. For the quarter ended March 31, 2026, total revenue was $6.5 million, down from $14.7 million a year earlier, mainly due to lower collaboration revenue from Roche as projects reached completion. Operating expenses fell to $135.0 million from $206.1 million, driven by reduced platform spending, no new Tempus data purchases, and lower stock-based compensation and G&A after portfolio reprioritization and prior-year Exscientia-related costs. Net loss narrowed to $117.5 million from $202.5 million. Cash, cash equivalents and restricted cash were $665.2 million, and the company expects this to fund operations for at least 12 months while it advances a broad AI-enabled pipeline and major collaborations with Sanofi, Merck and Roche/Genentech. Recursion also has a $300 million at-the-market equity program available but unsused this quarter and continues to report material weaknesses in internal control over financial reporting related to the Exscientia acquisition, with remediation efforts ongoing.
Recursion Pharmaceuticals, Inc. reported first-quarter 2026 revenue of $6.5 million, down from $14.7 million a year earlier, and a narrower net loss of $117.5 million versus $202.5 million. The company ended the quarter with $665.2 million in cash, cash equivalents and restricted cash and reiterated guidance for 2026 operational cash burn of less than $390 million, supporting runway into early 2028.
Operating efficiency improved, with research and development expenses falling to $87.9 million from $129.6 million and general and administrative expenses to $34.6 million from $54.7 million. Cash operating expense declined to $85.1 million from $120.2 million, driven by lower platform costs, improved efficiency and fewer one-time items.
The AI-driven pipeline advanced, including favorable early Phase 1 data for REC‑1245 showing it was well tolerated with no dose-limiting toxicities in 16 solid-tumor patients, strong Phase 2 efficacy signals for REC‑4881 in familial adenomatous polyposis with up to 53% median polyp reduction and 40% of patients improving in Spigelman stage, and first patient dosed in Phase 1 for REC‑4539, a brain-penetrant LSD1 inhibitor.
Issuer filed a Rule 144 notice reporting restricted Class A shares sold under Rule 144. The filing lists sales by Blake C. Borgeson of 170,000 shares on 03/03/2026 for $588,200 and 30,000 shares on 04/07/2026 for $93,000. It also shows an earlier 30,000-share issuance dated 09/19/2017 labeled "Founders Shares" and a broker record for 30,000 shares at Fidelity Brokerage Services.
Recursion Pharmaceuticals, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 17, 2026 at 12:00 P.M. Mountain Time. The agenda includes electing two Class II directors, an advisory “say‑on‑pay” vote on executive compensation, and ratifying PricewaterhouseCoopers LLP as independent auditor for 2026.
The company highlights its AI‑native TechBio business model, dual‑class share structure with Class A at one vote and Class B at ten votes per share, and a 10‑member, largely independent and diverse board. It details virtual‑only participation, broker voting rules, and committee responsibilities for audit, compensation, governance, R&D, technology, social responsibility, and strategic transactions.
Recursion outlines a pay‑for‑performance philosophy, with 2025 annual incentives paid at 80% of target and a heavy emphasis on stock options and RSUs. The proxy also describes a CEO transition effective January 1, 2026 from co‑founder Christopher Gibson to Najat Khan and raises outside director retainers and equity awards starting April 1, 2026.
Recursion Pharmaceuticals announced a planned board transition involving its founder and current Chair, Chris Gibson, Ph.D. On April 28, 2026 he informed the company that he will not stand for re-election as a Class II director at the 2026 Annual Meeting of Stockholders.
The filing states his decision is not due to any disagreement with the company on operations, policies, or practices. Dr. Gibson will continue serving as Chair of the Board and on its committees through the end of his current term and will remain involved as a strategic advisor thereafter, supporting leadership continuity.